JWH-175
 | |
|---|---|
| Systematic (IUPAC) name | |
| (1-pentylindol-3-yl)naphthalen-1-ylmethane | |
| Clinical data | |
| Legal status | Illegal in Russia, UK and some states in USA and Australia |
| Identifiers | |
| CAS number | 619294-35-8  |
| ATC code | ? |
| PubChem | CID 56603534 |
| Chemical data | |
| Formula | C24H25N |
| Mol. mass | 327.461 g/mol |
| SMILES
| |
JWH-175 is a drug from the naphthylmethylindole family which acts as a cannabinoid receptor agonist. It was invented by the scientist John W. Huffman and colleagues at Clemson University. JWH-175 is closely related to the widely used cannabinoid designer drug JWH-018, but with the ketone bridge replaced by a simpler methylene bridge. It is several times weaker than JWH-018, having a binding affinity at the CB1 receptor of 22nM, though some derivatives substituted at the 4-position of the naphthyl ring have potency more closely approaching that of the equivalent naphthoylindoles.[1] This makes JWH-175 considerably less potent than most synthetic cannabinoid drugs used in synthetic cannabis blends, and it is unclear if JWH-175 has ever been used for this purpose. However it has still been explicitly banned in several jurisdictions including Russia and some Australian states, in order to stop its potential use as an ingredient in such products.
See also
References
- ↑ Huffman JW, Padgett LW. Recent Developments in the Medicinal Chemistry of Cannabimimetic Indoles, Pyrroles and Indenes. Current Medicinal Chemistry, 2005; 12: 1395-1411.